Cardiol hits MAVERIC enrollment target early, expands trial to 150 patients

Cardiol Therapeutics said on September 23, 2026 that it had reached its original enrollment target in the pivotal Phase III MAVERIC trial ahead of schedule. As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance.¹

The trial is testing CardiolRx™ in patients with recurrent pericarditis, and the company describes it as a pivotal Phase III randomized, double-blind, placebo-controlled, multi-center trial evaluating CardiolRx™ for the reduction in risk of recurrence in patients with recurrent pericarditis¹.

The trial's steering committee has now recommended growing the study further. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk.¹ That recommendation follows an interim look at the data. The recommendation follows a blinded review showing fewer-than-expected recurrences, an observation the Company views as encouraging.¹

As a result, the timeline for results has shifted. Topline results are now anticipated in mid-2027, compared with the company's previous Q1 2027 guidance.¹ Cardiol said it has funding in place to see the study through. Existing capital is expected to fund MAVERIC completion, with cash runway into Q1 2028.¹

On endpoints, the release states the primary efficacy analysis will assess time to a first new episode of pericarditis recurrence, evaluating the ability of CardiolRx™ to delay or prevent recurrence over time¹, with the proportion of patients free from a new episode of recurrent pericarditis at the end of the study assessed as a secondary endpoint¹.

The drug already carries Orphan Drug Designation from the U.S. FDA for the treatment of pericarditis, including recurrent pericarditis¹.